SCHEMBL4324403

SCHEMBL4324403

CCOC(=O)c1nc(CN2CCOCC2)c2ccccn12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 4/20 0.60
CNR2 P34972 4/20 0.60
ALDH1A1 P00352 6/20 0.47
TSHR P16473 4/20 0.47
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
NPSR1 Q6W5P4 3/20 0.44
KDM4E B2RXH2 3/20 0.44
GAA P10253 2/20 0.44
HPGD P15428 2/20 0.44
HSD17B10 Q99714 1/20 0.44
RXFP1 Q9HBX9 1/20 0.43
MAPK1 P28482 3/20 0.43
MAPT P10636 3/20 0.43
LMNA P02545 2/20 0.43
STAT3 P40763 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
SLC2A1 P11166 1/20 0.43
NPY1R P25929 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2743126 0.86 CNR2 (0.61) CNR1CNR2ALDH1A1TSHRNPSR1
SCHEMBL2743123 0.85 CNR1 (0.68) CNR1CNR2ALDH1A1KMT2AKDM4E
SCHEMBL4324386 0.84 ALDH1A1 (0.44) CNR1CNR2ALDH1A1TSHRMEN1
SCHEMBL18039524 0.83 CNR1 (0.66) CNR1CNR2ALDH1A1KDM4EGAA
SCHEMBL4325408 0.82 CNR2 (0.47) CNR1CNR2ALDH1A1TSHRMEN1
SCHEMBL4461480 0.81 CNR1 (0.69) CNR1CNR2ALDH1A1KMT2AKDM4E
SCHEMBL230100 0.81 CNR1 (0.58) CNR1CNR2KDM4EGAAHPGD
SCHEMBL13578120 0.79 CNR1 (0.56) CNR1CNR2ALDH1A1TSHRNPSR1
SCHEMBL4341215 0.78 CNR1 (0.62) CNR1CNR2ALDH1A1TSHRHPGD
SCHEMBL4326889 0.77 CNR1 (0.70) CNR1CNR2ALDH1A1TSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090325936-A1 IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES MERCK & CO., INC. 2009-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325936-A1 IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES CNR2, CNR1, TRPV1 CNR1 2/4885CNR2 1/4885ALDH1A1 2838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.